Drug Shortage Report for APO-RIVASTIGMINE
| Report ID | 221729 |
| Drug Identification Number | 02336715 |
| Brand name | APO-RIVASTIGMINE |
| Common or Proper name | RIVASTIGMINE |
| Company Name | APOTEX INC |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 1.5MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 100 BTL |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-03-05 |
| Estimated end date | 2024-05-10 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2024-03-22 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
| Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2024-03-22 | French | Compare |
| v3 | 2024-03-22 | English | Compare |
| v2 | 2024-03-08 | French | Compare |
| v1 | 2024-03-08 | English | Compare |
Showing 1 to 4 of 4